^
Association details:
| Biomarker: | BRAF V600K |
|---|---|
| Cancer: | Melanoma |
| Drug: | elraglusib (9-ING-41) (GSK3β inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3ß) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors.
Published date:
05/13/2020
Excerpt:
One BRAFV600K-mutated melanoma with > 20 brain metastases, post checkpoint/BRAF/MEK failure has an ongoing CR starting at cycle 2 and sustained after 9 months on treatment.
DOI:
10.1200/JCO.2020.38.15_suppl.3507
